Expertise in
1
conditions

Laurent Pascal

Lille, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Lille, FR 

Overview

Laurent Pascal practices practicing medicine in Lille, France.

Mr. Pascal is highly rated in 1 condition, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Monoblastic Leukemia (AmoL), Chronic Myelomonocytic Leukemia (CMML), and Adult Immune Thrombocytopenia.

He is actively involved in clinical research, co-authoring 37 peer reviewed articles and participating in 8 clinical trials.

Gender

Male

Locations

Lille, France
Other Locations
CH Roubaix
Roubaix, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Enrollment Status: Recruiting
Publish Date: March 05, 2026
Intervention Type: Drug
Study Drugs: Luspatercept, Eprex
Study Phase: Phase 1/Phase 2
Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F Positive Chronic Myeloproliferative Neoplasms
Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F Positive Chronic Myeloproliferative Neoplasms
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC
Enrollment Status: Completed
Publish Date: August 02, 2024
Intervention Type: Other
Study Phase: Not Applicable
Impact of 2 Transfusion Strategies on the Quality of Life of Multi-transfused Patients With Low Risk Myelodysplastic Syndrome: Multicenter Randomized Trial Comparing a Liberal vs. Restrictive Transfusion Regimen
Impact of 2 Transfusion Strategies on the Quality of Life of Multi-transfused Patients With Low Risk Myelodysplastic Syndrome: Multicenter Randomized Trial Comparing a Liberal vs. Restrictive Transfusion Regimen
Enrollment Status: Terminated
Publish Date: June 23, 2023
Intervention Type: Other
Study Phase: Not Applicable
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: Romidepsin, CHOP
Study Phase: Phase 3
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
Enrollment Status: Completed
Publish Date: October 04, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)
A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Drugs: Decitabine, Hydroxyurea
Study Phase: Phase 3
Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association
Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association
Enrollment Status: Completed
Publish Date: April 13, 2021
Intervention Type: Drug
Study Drugs: Lenalidomide, Rituximab
Study Phase: Phase 3
View 7 Less Clinical Trials

37 Total Publications

9-Year Serial CMR Monitoring of Cardiac AL Amyloidosis Regression After Teclistamab.
9-Year Serial CMR Monitoring of Cardiac AL Amyloidosis Regression After Teclistamab.
Journal: JACC. Case reports
Published: April 16, 2026

Frequently Asked Questions about Laurent Pascal

Is Laurent Pascal a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Laurent Pascal is classified as an Advanced expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Laurent Pascal participate in research or clinical trials?

Yes. Laurent Pascal has published 37 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Laurent Pascal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Pascal's expertise for a condition
ConditionClose
      View All 22 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile